Nurix Therapeutics (NASDAQ:NRIX) Research Coverage Started at Leerink Partners

Leerink Partners started coverage on shares of Nurix Therapeutics (NASDAQ:NRIX) in a report published on Monday morning, MarketBeat Ratings reports. The brokerage issued a market perform rating and a $16.00 target price on the stock.

Several other equities research analysts also recently weighed in on the stock. Needham & Company LLC decreased their price target on shares of Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Morgan Stanley lifted their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Monday, February 3rd. HC Wainwright lifted their price objective on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. BTIG Research started coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Royal Bank of Canada boosted their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.88.

Nurix Therapeutics Trading Up 1.8 %

NRIX opened at $13.90 on Monday. Nurix Therapeutics has a 1-year low of $11.90 and a 1-year high of $29.56. The company has a market cap of $1.05 billion, a P/E ratio of -4.81 and a beta of 2.18. The company has a fifty day moving average price of $17.22 and a two-hundred day moving average price of $20.93.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, research analysts forecast that Nurix Therapeutics will post -2.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $55,798.35. Following the sale, the chief financial officer now owns 39,549 shares of the company’s stock, valued at $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,326 shares of company stock valued at $213,449. Company insiders own 7.20% of the company’s stock.

Institutional Trading of Nurix Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of NRIX. US Bancorp DE raised its position in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after purchasing an additional 842 shares during the period. GF Fund Management CO. LTD. bought a new stake in Nurix Therapeutics during the 4th quarter worth approximately $28,000. Amalgamated Bank increased its holdings in Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after acquiring an additional 511 shares during the period. Quarry LP increased its holdings in Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after acquiring an additional 2,435 shares during the period. Finally, Aquatic Capital Management LLC bought a new stake in Nurix Therapeutics during the 4th quarter worth approximately $87,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.